AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Atea Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$4.39+0.07 (+1.62%)

Close on Oct 19, 2026

Market cap: $351.42M
P/E (TTM): –
Dividend yield: –

Atea Pharmaceuticals, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31	Q4 2019 2019-12-31	Q3 2019 2019-09-30
Depreciation & Amortization	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.10	0.11	0.04	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00
Stock-Based Compensation	3.38	3.73	4.59	4.52	4.67	6.95	14	12	13	13	12	12	12	13	12	12	12	12	11	11	10	7.27	2.82	4.24	0.21	0.19	0.17	0.16
Change in Accounts Payable	0.61	-3.50	9.43	-5.33	1.46	2.93	-1.33	0.32	-16	17	3.86	-3.57	3.26	-1.85	1.43	-13	10	-0.88	-18	11	13	3.73	-4.18	1.05	2.79	-0.15	0.45	–
Change in Unearned Revenue	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-192	-33	-10	-66	–	–	–	–	–	–
Operating Cash Flow	-37	-46	-28	-40	-33	-31	-30	-23	-42	-40	-22	-18	-16	-30	-22	-21	-19	-59	-75	23	-17	-17	319	-9.48	-7.80	-4.51	-3.94	–
Capital Expenditures	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	-0.02	-1.88	-0.04	–	–	–	–	-0.01	-0.02	–	–	0	–
Purchase of Investments	-34	-75	-44	-15	-101	-123	-58	-228	-7.26	-167	-47	-205	-153	-157	-58	–	–	–	–	–	–	–	–	–	–	–	–	–
Sale & Maturity of Investments	68	104	90	56	116	208	55	106	132	224	75	147	200	181	92	0	–	–	–	–	–	–	–	–	–	–	–	–
Investing Cash Flow	34	30	47	41	15	86	-3.37	-122	125	57	28	-59	47	24	33	-487	-1.88	-0.04	–	–	–	–	-0.01	-0.02	–	–	0	–
Share Repurchases	–	–	0	-11	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Taxes Paid on Share-Based Awards	0	-0.75	0	0	0	-0.49	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financing Cash Flow	0	0.26	0	-11	-14	-0.35	0	0.12	0	0.15	0	0.09	0	0.17	0	0.15	0	0.22	0.14	0.80	0.06	0.47	426	-0.91	106	-0.01	–	–
Net Change in Cash	-2.77	-16	18	-10	-32	55	-34	-145	82	17	5.94	-76	30	-5.21	12	-508	-21	-59	-75	23	-17	-16	745	-10	99	-4.51	-3.94	–
Free Cash Flow	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-22	-21	-21	-59	–	–	–	–	319	-9.50	–	–	-3.94	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -44.3%

Financial strength

Current ratio: 8.13
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 272.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.72
Dividend yield: –